Get the Stockscreener App
22.86
3.53%
0.76
After Hours:
22.86
Pacira Biosciences Inc stock is traded at $22.86, with a volume of 761.59K.
It is up +3.53% in the last 24 hours and up +10.64% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$22.10
Open:
$22.12
24h Volume:
761.59K
Relative Volume:
0.86
Market Cap:
$939.55M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
15.77
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-2.47%
1M Performance:
+10.64%
6M Performance:
-14.40%
1Y Performance:
-2.76%
1-Day Range:
$21.87
$22.99
1-Week Range:
$20.62
$23.73
52-Week Range:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.86 | 908.31M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
PCRX Earnings History & Surprises | EPS & Revenue Results | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - Sahm
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - Sahm
Pacira BioSciences Q4 Earnings Call Highlights - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira BioSciences Inc. (PCRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Q4 Earnings Assessment - Benzinga
BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million - TradingView
Pacira BioSciences, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside - DirectorsTalk Interviews
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Pacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Can Pacira BioSciences Inc expand its profit margins2025 Valuation Update & Detailed Earnings Play Alerts - baoquankhu1.vn
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court - TipRanks
Can Pacira BioSciences Inc. stock deliver sustainable ROEQuarterly Profit Review & AI Driven Stock Reports - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
MSN Money - MSN
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Closer Look at Its 36.49% Potential Upside - DirectorsTalk Interviews
Is Pacira BioSciences Inc. trading at a discountEarnings Risk Report & Consistent Profit Trade Alerts - mfd.ru
Understanding Momentum Shifts in (PCRX) - Stock Traders Daily
Will Pacira BioSciences Inc. (82P) stock gain from lower interest ratesWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Should you avoid Pacira BioSciences Inc. stock right nowLong Setup & AI Enhanced Trading Signals - mfd.ru
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Should you avoid Pacira BioSciences Inc stock right nowJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Pacira BioSciences (PCRX) CEO receives 261,818 stock units award - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 - GlobeNewswire
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):